Potent antileukemia interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

Leukemia

Volumn 18, Issue 11, 2004, Pages 1780-1788

  Rosato, R R ^a   Dai, Y ^a   Almenara, J A ^a   Maggio, S C ^a   Grant, S T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Flavopiridol; TRAIL; XIAP

Indexed keywords

ANTILEUKEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CASPASE; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; CYTOKINE RESPONSE MODIFIER A; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLAVOPIRIDOL; FLICE INHIBITORY PROTEIN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BID PROTEIN, HUMAN; BIRC4 PROTEIN, HUMAN; CARRIER PROTEIN; COMPLEMENT; DIABLO PROTEIN, HUMAN; FLAVONOID; FLAVOPROTEIN; GLYCOPROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; MITOCHONDRIAL PROTEIN; PARP1 PROTEIN, HUMAN; PDCD8 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN; PROTEIN BCL X; SC5B 9 PROTEIN COMPLEX; SC5B-9 PROTEIN COMPLEX; SIGNAL PEPTIDE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL STRAIN U937; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOMINANT GENE; DOWN REGULATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE CONSTRUCT; GENETIC STABILITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LETHALITY; LEUKEMIA CELL LINE; MITOCHONDRION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; STATISTICAL SIGNIFICANCE; CELL CYCLE; CELL STRAIN HL 60; DRUG EFFECT; DRUG INTERACTION; GENETICS; LEUKEMIA; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARRIER PROTEINS; CASPASES; CELL CYCLE; COMPLEMENT SYSTEM PROTEINS; CYTOCHROMES C; DOWN-REGULATION; DRUG INTERACTIONS; DRUG SYNERGISM; FLAVONOIDS; FLAVOPROTEINS; GLYCOPROTEINS; HL-60 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LEUKEMIA; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MULTIPLE MYELOMA; PHOSPHORYLATION; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 8844228917     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403491     Document Type: Article

References (54)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
2. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15: 1022-1032.
3. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900-3906.
4. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001; 81: 380-390.
5. Cartee L, Smith R, Dai Y, Rahmani M, Rosato R, Almenara J et al. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol Pharmacol 2002; 61: 1313-1321.
6. Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp Cell Res 2002; 277: 31-47.
7. Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Mol Pharmacol 2003, 63: 232-242.
8. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2: 1273-1284.
9. Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 2001; 8: 715-724.
10. Pepper C, Thomas A, Fegan C, Hoy T, Bentley P. Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymph 2003; 44 337-342.
11. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiriclol. Blood 1998; 91: 458-465.
12. Semenov I, Akyuz C, Roginskaya V, Chauhan D, Corey SJ. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 2002; 26: 271-280.
13. Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY et al. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003; 63: 621-626.
14. Wang Z, Van Tuyle G, Conrad D, Fisher PB, Dent P, Grant S. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Cancer Res 1999; 59: 1259-1267.
15. Datta R, Oki E, Endo K, Biedermann V, Ren J, Kufe D. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem 2000; 275: 31733-31738.
16. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16: 1331-1343.
17. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 2001; 19 181-191.
18. Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem Pharmacol 2000; 60: 1445-1456.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
20. Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1: 90-96.
21. Cartee L, Maggio SC, Smith R, Sankala HM, Dent P, Grant S. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol Cancer Ther 2003; 2: 83-93.
22. Bedi A, Barber JP, Bedi GC, El Deiry WS, Sidransky D, Vala MS et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.
23. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281.
24. Deng Y, Lin Y, Wu X, TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16: 33-45.
25. Roth W, Reed JC. Apoptosis and cancer: when BAX is TRAILing away. Nat Med 2002; 8: 216-218.
26. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH et al. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001; 130: 265-272.
27. Bratton SB, Cohen GM. Death receptors leave a caspase footprint that Smacs of XIAP. Cell Death Differ 2003; 10: 4-6.
28. Decker RH, Wang S, Dai Y, Dent P, Grant S. Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biol Ther 2002; 1: 136-144.
29. Kroemer C, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-519.
30. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
31. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63: 93-99.
32. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M et al. Raf-1 and bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003; 9: 1161-1170.
33. Gallo G, Giarnieri E, Bosco S, Cappelli C, Alderisio M, Giovagnoli MR et al. Aberrant bcl-2 and bax protein expression related to chemotherapy response in neuroblastoma. Anticancer Res 2003; 23: 777-784.
34. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003; 4: 211-218.
35. Kim EJ, Suliman A, Lam A, Srivastava RK. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand. Int J Oncol 2001; 18 187-194.
36. Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett 2000; 471: 93-98.
37. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine 1999; 11: 1010-1019.
38. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21: 2283-2294.
39. Wang S, Wang Z, Boise L, Dent P, Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 1999; 259: 67-72.
40. Ng C-P, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Therap 2002; 1: 1051-1058.
41. Sun XM, Bratton SB, Butterworth M, MacFarlane M, Cohen GM. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 2002; 277 11345-11351.
42. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by SMAC/DIABLO release from mitochondria. Cancer Res 2001; 61: 7339-7348.
43. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17: 2215-2223.
44. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446.
45. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001; 2: RESEARCH0041.
46. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276: 31793-31799.
47. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275: 28345-28348.
48. Johnson DE, Gastman BR, Wieckowski E, Wang GQ, Amoscato A, Delach SM et al. Inhibitor of apoptosis protein hILP undergoes caspase-mediated cleavage during T lymphocyte apoptosis. Cancer Res 2000; 60: 1818-1823.
49. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288: 874-877.
50. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10: 169-177.
51. Cummins JM, Kohli M, Rago, C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64: 3006-3008.
52. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003; 18: 1-6.
53. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-2999.
54. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.